Patents

Acura actively pursues patents and trademark protection for our business interests. In addition to our issued U.S. patents, we have filed multiple U.S. patent applications and international patent applications relating to compositions containing abusable active pharmaceutical ingredients as well as applications covering our IMPEDE™ Technology. Except for those rights conferred in the Pfizer Agreement, Acura has retained all intellectual property rights to our technologies and related product candidates.

Reference is made to the Risk Factors link on this web site and contained in our filings with the Securities and Exchange Commission for a discussion, among other things, of patent applications and patents owned by third parties including claims that may encompass our AVERSION® Technology and OXECTA® tablets.

Issued Patents

 Patent Number Jurisdiction Allowed Claims General Subject
7,201,920 U.S. 54 Compositions intended to deter the most common methods of prescription opioid analgesic product misuse and abuse. These patented pharmaceutical compositions include the mixture of functional inactive ingredients and specific opioid analgesics such as oxycodone HCl and hydrocodone bitartrate among others.
7,510,726 U.S. 20 Compositions and a wider range (compared to the 920 Patent) of functional inactive ingredients intended to deter the most common methods of prescription opioid analgesic product misuse and abuse.
7,981,439 U.S. 7 Compositions including any water soluble drug of abuse intended to deter the most common methods of prescription opioid analgesic product misuse and abuse. We believe our stimulant product candidate currently in development is encompassed by the 439 Patent.

7,476,402 U.S. 18 Compositions including certain combinations of kappa and mu opioid receptor agonists intended to deter opioid analgesic product misuse and abuse.
8,101,630 U.S. 1 Extended release abuse deterrent dosage form of oxycodone or a pharmaceutically acceptable salt thereof.
7,071,336 U.S. 21 Process for manufacturing opioid analgesics.
8,409,616 U.S. 17 Encompass certain immediate-release abuse deterrent dosage forms.
8,637,540 U.S. 21 Encompass certain immediate-release abuse deterrent opioid products.

Pending Patents

In addition to our issued U.S. Patents, we have filed multiple U.S. patent applications and international patent applications relating to compositions containing abusable active pharmaceutical ingredients as well as applications covering our IMPEDE® Technology. Except for those rights conferred in the Pfizer Agreement, we have retained all intellectual property rights to our AVERSION® Technology, IMPEDE® Technology, and related product candidates.